| |
Carol Lowry Senior food scientist Cargill
|
On Feb. 21, 2012, the U.S. Food and Drug Administration (FDA) announced that it would allow continued use of the health claim linking consumption of free plant sterols as well as sterol esters to a reduced risk of coronary heart disease until a final rule is issued. It was good news in that food and dietary supplement manufacturers can keep using free sterols in applications such as beverages and tablets, but the lack of a final decision on health claim requirements may spell continued uncertainty for some of these manufacturers.
FDA’s recent review of the sterols health claim also spurred interesting discussions of the relative merits of and differences between sterol esters and free sterols. At Cargill, we stay on top of regulatory issues so we can inform our customers on FDA’s actions like the proposed amendment of the sterol/heart disease risk reduction health claim. We extend our expertise to our customers to identify which version of sterol ingredient is best for their particular application now and, if the FDA issues a final decision on the health claim at some point in the future, what it might mean for them.
From
'Formulating Ideas'